Patient-Oriented Evidence That Matters

Colchicine Reduces MI and Revascularization in Patients with Established Coronary Artery Disease


Am Fam Physician. 2021 May 15;103(10):631-632.

Clinical Question

Does colchicine reduce the risk of cardiovascular events in patients with chronic coronary artery disease?

Bottom Line

Colchicine, 0.5 mg daily, significantly reduces the risk of myocardial infarction (MI) and ischemia-driven revascularization. For the compositive outcome of cardiovascular death, MI, or ischemic stroke, the number needed to treat (NNT) was 67 over 29 months. The cost is $8 per month in Canada and $65 per month in the United States. There was increased noncardiovascular mortality, but no clear pattern with regard to cause of death. (Level of Evidence = 1b)


Colchicine has been shown to reduce a broad composite of cardiovascular outcomes in patients with recent MI, and a small open-label trial of patients with chronic coronary artery disease showed a similar outcome. The authors identified 6,528 patients, 35 to 82 years of age, with documented coronary artery disease on computed tomography angiogram, by invasive angiography, or with a coronary artery calcium score of at least 400 Agatston units. Patients with at least moderate renal disease, severe valvular heart disease, or heart failure were excluded, as were those who were intolerant of colchicine. The study began with an open-label run-in period that excluded 15% of patients, largely because of drug adverse effects. The remaining 5,522 were randomized to receive colchicine, 0.5 mg once daily, or placebo. Analysis was by intention to treat, and groups were similar at baseline. The patients' mean age was 66 years, 15% were women, 12% were smokers, and 18% had diabetes. Most had a previous revascularization, largely stenting. All patients were from the Netherlands (66%) or Australia (34%). Patients were followed up for a median of 29 months, and 10.5% in each group stopped taking the medication or placebo. There were no differences between groups in withdrawals or perceived adverse effects. The authors examined four different composite outcomes. They found a reduction in the primary

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP

More in Pubmed


Jan 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article